Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published July 2013 | Supplemental Material + Published
Journal Article Open

MicroRNA‐146 represses endothelial activation by inhibiting pro‐inflammatory pathways

Abstract

Activation of inflammatory pathways in the endothelium contributes to vascular diseases, including sepsis and atherosclerosis. We demonstrate that miR-146a and miR-146b are induced in endothelial cells upon exposure to pro-inflammatory cytokines. Despite the rapid transcriptional induction of the miR-146a/b loci, which is in part mediated by EGR-3, miR-146a/b induction is delayed and sustained compared to the expression of leukocyte adhesion molecules, and in fact coincides with the down-regulation of inflammatory gene expression. We demonstrate that miR-146 negatively regulates inflammation. Over-expression of miR-146a blunts endothelial activation, while knock-down of miR-146a/b in vitro or deletion of miR-146a in mice has the opposite effect. MiR-146 represses the pro-inflammatory NF-κB pathway as well as the MAP kinase pathway and downstream EGR transcription factors. Finally, we demonstrate that HuR, an RNA binding protein that promotes endothelial activation by suppressing expression of endothelial nitric oxide synthase (eNOS), is a novel miR-146 target. Thus, we uncover an important negative feedback regulatory loop that controls pro-inflammatory signalling in endothelial cells that may impact vascular inflammatory diseases.

Additional Information

© 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. This is an open access article under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Received December 01, 2012. Revised April 26, 2013. Accepted April 29, 2013. We thank D. Srivastava (Gladstone Institute of Cardiovascular Disease) for providing reagents and mentorship, and E. Flemington (Tulane University Health Sciences Center), and J.D. Powell (John Hopkins) for providing reagents. We thank J. Wythe (Gladstone Institute of Cardiovascular Disease) for critical comments on the manuscript. Research in the laboratory of JEF was supported by a Heart and Stroke Foundation of Ontario Grant‐in‐aid (NA 7282) and the Canadian Institutes of Health Research (OCN‐126570). Research in the laboratory of MC is supported by grants from the Heart and Stroke Foundation of Ontario and the Canadian Institutes of Health Research. PDO is supported by Operational Funding from the Hospital for Sick Children Research Institute. JEF is the recipient of a New Investigator Award from the Heart and Stroke Foundation of Canada and an Early Researcher Award from the Ontario Ministry of Economic Development and Innovation, and has received funding from the Leaders Opportunity Fund from the Canadian Foundation for Innovation. Supporting Information is available at EMBO Molecular Medicine online. The authors declare that they have no conflict of interest. Author contributions: HSC and NS designed and performed experiments, and analysed data. EB, AL, PDO and JLZ performed experiments. DB supervised JLZ and provided reagents. MIC supervised AL and designed experiments. JEF designed and performed experiments, analysed data and wrote the manuscript. All authors approved the final manuscript.

Attached Files

Published - emmm201202318.pdf

Supplemental Material - emmm201202318-sm-0002-SupData-S1.pdf

Supplemental Material - emmm201202318.reviewer_comments.pdf

Files

emmm201202318.pdf
Files (4.4 MB)
Name Size Download all
md5:e3ba02cc62e001f44b9d58a4e0ecf40e
1.1 MB Preview Download
md5:311fbcd744052c923411a4cbda1c9d26
390.5 kB Preview Download
md5:03edcf2a67d118b2d6a7607e9b9b5272
2.9 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 25, 2023